Investigational drug · Phase 3
proposed biosimilar to etanercept
Also called: MB04
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Rheumatoid Arthritis (RA).
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "proposed biosimilar to etanercept"
First trial start
2024
Oct 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "proposed biosimilar to etanercept", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis (RA)
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "proposed biosimilar to etanercept" as an intervention, largest first.
- A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate TherapyPivotal-lookingCompleted
Samsung Bioepis Co., Ltd.Industry
NCT01895309 · 596 participants · Start Jun 2013 · Primary completion Apr 2014
Drug: Enbrel (etanercept); SB4 (proposed biosimilar to etanercept) · For: Rheumatoid Arthritis
Sites: Kielce, Poland; Southampton, United Kingdom
- A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid ArthritisPivotal-lookingCompleted
mAbxience Research S.L.Industry
NCT06596772 · 501 participants · Start Oct 3, 2024 · Primary completion Feb 20, 2026
Drug: MB04 (proposed biosimilar to etanercept); Enbrel (etanercept) · For: Rheumatoid Arthritis (RA)
Sites: Haskovo, Bulgaria; Plovdiv, Bulgaria; Rousse, Bulgaria · 60 sites in all
- A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune DisordersPivotal-lookingCompleted
mAbxience Research S.L.Industry
NCT06392074 · 141 participants · Start Mar 7, 2024 · Primary completion May 12, 2025
Drug: MB04; US License Enbrel and 1 more · For: Healthy Volunteers
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Mycobacterium bovis Strain-Dependent Effects of ESAT-6 and CFP-10 on Inflammasome Activation in Bovine Macrophages.
Blanco FC, Vazquez CL, Bigi MM, et al. · Int J Mol Sci 2026
- A Transcriptional Analysis of Cattle Immune Cells Reveals a Central Role of Type 1 Interferon in the In Vitro Innate Immune Response against Mycobacterium bovis.
Blanco FC, Bigi MM, García EA, et al. · Pathogens 2023
- Replication and transmission features of two experimental vaccine candidates against bovine tuberculosis subcutaneously administrated in a murine model.
Muñiz XF, García EA, Blanco FC, et al. · Tuberculosis (Edinb) 2022
Also in development for Rheumatoid Arthritis (RA)
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
Beijing VDJBio Co., LTD. · Anti IL-6R, Idiopathic Multicentric Castleman's Disease, Castleman's Disease, Multicentric
- AP1189Phase 23 trials
SynAct Pharma Aps · Rheumatoid Arthritis (RA), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy
- QLS12010Phase 23 trials
Qilu Pharmaceutical Co., Ltd. · Adults With Moderate-to-severe Hidradenitis Suppurativa, Moderate-to-severe Atopic Dermatitis, Rheumatoid Arthritis (RA)
- JAB-8263Phase 22 trials
Jacobio Pharmaceuticals Co., Ltd. · Rheumatoid Arthritis (RA), NSCLC, SCLC
- TollB-001Phase 22 trials
Toll Biotech Co. Ltd. (Beijing) · Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
- FT839Phase 21 trial
Fate Therapeutics · ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA)
- QEL-005Phase 21 trial
Quell Therapeutics Limited · Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.